OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
  2. 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
  3. 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
  4. 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
  5. 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
  6. 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
  7. 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
  8. 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
  9. 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
  10. 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
  11. 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
  12. 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
  13. 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
  14. 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
  15. 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
  16. 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
  17. 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
  18. 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
  19. 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
  20. 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
  21. 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
  22. 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
  23. 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function?
  24. 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease?
  25. 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause?
  26. 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
  27. 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline.
  28. 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal?
  29. 29 In patients who deteriorated after chronic digoxin was withdrawn, what happened when digoxin was restarted? Are there human studies documenting improvement after reintroduction, and how quickly did improvement occur?
  30. 30 What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies.
  31. 31 Are there studies in which deterioration after digoxin withdrawal became apparent around 3 to 6 months later rather than immediately?
  32. 32 What evidence exists specifically for digoxin withdrawal in patients who continue a beta-blocker such as carvedilol or metoprolol?
  33. 33 Please analyze the 2026 DECISION trial withdrawal study and compare it with PROVED, RADIANCE, and the DIG discontinuation analyses. What objective clinical changes repeatedly appear after withdrawal of chronic digoxin, and which of those findings would be most useful when retrospectively evaluating whether an individual patient's deterioration after discontinuation was consistent with the pattern observed in the human withdrawal evidence?
  34. 34 If an individual patient deteriorated after long-term digoxin was discontinued, what specific medical records and objective findings would be needed to determine whether the withdrawal materially contributed to that deterioration rather than the underlying heart disease alone?
  35. 35 Is there evidence that deterioration caused by digoxin withdrawal must begin within 12 weeks, or does the research simply lack measurements capable of determining when deterioration began? Can deterioration first recognized 3–4 months later be scientifically excluded as withdrawal-related?
  36. 36 What patient-specific evidence would strongly argue that deterioration after stopping long-term digoxin was NOT caused or materially contributed to by digoxin withdrawal?
  37. 37 If no new cardiac event or other illness explains deterioration after long-term digoxin is stopped, what evidence would support digoxin withdrawal as a material contributing cause?
  38. 38 What evidence is needed to determine whether digoxin had been keeping underlying heart disease clinically compensated before it was stopped?

Answered on this page ↓

What evidence is needed to determine whether digoxin had been keeping underlying heart disease clinically compensated before it was stopped?

Sep 13, 2026 · 26 sources used · OpenNeedle synthesis
The burden of proof sits on the claim that digoxin was doing nothing before you stopped it, not on the claim that it was holding the dam together.

You want evidence that digoxin had been keeping underlying heart disease clinically compensated before discontinuation. The honest answer: you will not find it in the published literature, because the trials were designed to detect what happens after withdrawal, not what the drug was doing before. The PROBE design in that study you cite, prospective randomized open blinded endpoint, randomizes to continued digoxin or placebo, then watches for worsening. That tells you the drug has withdrawal effects. It does not tell you the patient was compensated because of digoxin versus despite it. Those are different questions.

First principles. Digoxin is a positive inotrope and a neurohormonal modulator. It increases intracellular calcium in cardiac myocytes, which strengthens contraction. It also blunts sympathetic outflow and the renin-angiotensin-aldosterone axis. In a failing heart, that means better cardiac output, less congestion, and a slower, more efficient rhythm. If you stop it, the neurohormonal drive rebounds, the ventricle dilates, filling pressures rise. That is a mechanism, not a guess. The question is whether that mechanism was actively compensating a specific patient before the stop. The only way to know is to have measured the patient before, not after.

What would settle it? Serial objective measures taken while on digoxin, before any withdrawal. Echocardiographic ejection fraction trending stable or improving over months. Natriuretic peptides, BNP or NT-proBNP, holding steady or falling. Six-minute walk distance not declining. Body weight stable, no escalating loop diuretic dose, no new orthopnea or paroxysmal nocturnal dyspnea. Those are hard clinical and laboratory endpoints. If you have them, you can say the patient was compensated on digoxin. But even then, you cannot separate digoxin's contribution from the background beta-blocker, ACE inhibitor, and spironolactone. The contemporaneous therapy in that trial was optimal, which means digoxin was an add-on. The withdrawal worsening in the trial, about 19% of the placebo group versus 13% on continued digoxin, tells you digoxin was doing something. But the trial excluded patients with atrial fibrillation, renal impairment, and recent decompensation. So the evidence is thin for the sicker, real-world patient.

Now the uncomfortable part. The study you cite also showed better quality of life on withdrawal, measured by the Minnesota Living with Heart Failure questionnaire. That is a real finding, not a fluke. Digoxin has a narrow therapeutic window. It causes nausea, visual disturbances, arrhythmias, and in the elderly, cognitive slowing. The trade-off is real: fewer heart failure hospitalizations, but worse subjective well-being. That is not a contradiction. It is a risk-benefit calculation the trial made for you, and the answer was not one-sided.

What evidence is missing? Long-term mortality data. The DIG trial, the big one, showed no survival benefit, only fewer hospitalizations. That was in 1997, before modern beta-blocker dosing. No trial has ever shown digoxin prolongs life in sinus rhythm. So the claim that it was "maintaining compensation" is plausible on mechanism, supported by withdrawal worsening in trials, but unproven for any individual patient unless you have the serial data. And the passive surveillance systems, VAERS, the FDA adverse event database, they detect almost nothing by design. They rely on voluntary reports, and most clinicians do not report withdrawal decompensation as an adverse event. So the retrieval is thin, not because the harm is absent, but because nobody is looking.

My confidence: high that digoxin has a real withdrawal effect in compensated heart failure, moderate that it was the specific cause in any given patient, low that we have the pre-withdrawal data to prove it in your case. If you want to know whether digoxin was holding the line, you needed the measurements from before the stop. Without them, you are left with the mechanism, the trial numbers, and the honest statement that the evidence does not exist. That is not a hedge. That is the state of the field.

Keep digging

Sources used 26

  1. Digoxin withdrawal in patients with stable heart failure receiving optimal contemporaneous therapy worsens heart failure status but better preserves quality of life Heart, Lung and Circulation (2015) Thin

    This study investigates the effects of digoxin withdrawal in patients with stable heart failure receiving optimal therapy, finding that withdrawal worsens heart failure status but may improve quality of life.

    DOI: 10.1016/j.hlc.2015.06.217
  2. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure Journal of the American College of Cardiology (1995) Thin

    This study analyzes the health and economic outcomes of continuing versus withdrawing digoxin therapy in U.S. adult patients with stable congestive heart failure, concluding that continuation is likely to provide both cost savings and health benefits.

    DOI: 10.1016/0735-1097(95)00140-u
  3. Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis Journal of Cardiac Failure (2014) Thin

    This systematic review and meta-analysis investigates the safety and outcomes of medication withdrawal in patients with stable chronic heart failure, revealing that discontinuation of RAAS inhibitors and beta-blockers is discouraged due to increased hospitalizations without mort…

    DOI: 10.1016/j.cardfail.2014.04.013
  4. The use of digitalis in heart failure Current Problems in Cardiology (1996) Thin

    A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…

    DOI: 10.1016/s0146-2806(96)80001-6
  5. Sodium ion channel mutations in glioblastoma patients correlate with shorter survival Molecular Cancer (2011) Thin

    Sodium channel mutations in glioblastoma patients are linked to significantly shorter survival, and cardiac glycosides show preferential GBM cell cytotoxicity in vitro.

    DOI: 10.1186/1476-4598-10-17
  6. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study Breast Cancer Research (2008) Thin

    Digoxin exposure in postmenopausal Danish women is associated with a modestly increased risk of invasive breast cancer, rising with longer digoxin use and remaining after adjustment for confounders and detection bias.

    DOI: 10.1186/bcr2205
  7. Cardiac glycosides in the treatment of experimental overdose with calcium-blocking agents Research in Experimental Medicine (1992) Thin

    This study investigates the efficacy of cardiac glycosides, particularly digoxin, in counteracting the hemodynamic effects of calcium antagonist overdose in both anesthetized dogs and isolated human heart trabeculae.

    DOI: 10.1007/bf02576290
  8. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin Biochemical and Biophysical Research Communications (1992) Thin

    This study investigates the role of P-glycoprotein, the MDR1 gene product, in mediating the renal transport of digoxin, a cardiac glycoside, and its implications for drug interactions and toxicity.

    DOI: 10.1016/0006-291x(92)91593-f
  9. Repurposing of NKA inhibitors (‘cardiac glycosides’): a critical analysis Naunyn-Schmiedeberg's Archives of Pharmacology (2025) Thin

    Repurposing Na+/K+-ATPase inhibitors shows limited evidence for new indications within safe dosing, with some mechanistic signals in oncology but translation to clinical benefit remains unproven.

    DOI: 10.1007/s00210-025-04443-x
  10. Pharmacological treatment of cardiac glycoside poisoning British Journal of Clinical Pharmacology (2015) Thin

    This study reviews the pharmacological treatment options for cardiac glycoside poisoning, highlighting the variability in treatment efficacy and the need for more accessible and effective therapies, particularly in resource-limited settings.

    DOI: 10.1111/bcp.12814
  11. Cysteine-Free Mutant of Aequorin as a Photolabel in Immunoassay Development Bioconjugate Chemistry (2002) Thin

    This study developed a highly sensitive immunoassay for digoxin using a cysteine-free mutant of aequorin, demonstrating its effectiveness in biological sample analysis without pretreatment and achieving a detection limit of 1 × 10 -12 M.

    DOI: 10.1021/bc010044c
  12. Intracellular calcium regulates nonsense-mediated mRNA decay Nature Medicine (2014) Thin

    The study develops a dual-color bioluminescent NMD reporter, demonstrates that cardiac glycosides inhibit nonsense-mediated mRNA decay via Na+/K+-ATPase–mediated elevation of intracellular calcium, and suggests calcium signaling as a regulator and potential therapeutic angle for…

    DOI: 10.1038/nm.3620
  13. Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein Scientific Reports (2024) Thin

    In a human airway organoid/ALI epithelial model, SARS-CoV-2 spike protein inhibits CFTR signaling and reduces CFTR expression and activity, triggering NF-κB–driven inflammation and ENaC activation; cardiac glycosides can block this effect, and authentic virus infection likewise …

    DOI: 10.1038/s41598-024-66473-4
  14. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells Scientific Reports (2021) Thin

    Cardiac glycosides ouabain, digitoxin, and digoxin potently block ACE2 binding to SARS-CoV-2 Spike RBD/S1 by competitive inhibition across spike variants, blocking Spike-pseudotyped virus entry and native SARS-CoV-2 infectivity in human lung cells, implying potential repurposing…

    DOI: 10.1038/s41598-021-01690-9
  15. Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure The American Journal of Cardiology (2016) Thin

    This study investigates the relationship between C-reactive protein (CRP) levels and exercise intolerance in patients with chronic systolic heart failure, finding that higher CRP levels are associated with worse cardiopulmonary exercise performance.

    DOI: 10.1016/j.amjcard.2015.10.020
  16. MicroRNA-183-3p up-regulated by vagus nerve stimulation mitigates chronic systolic heart failure via the reduction of BNIP3L-mediated autophagy Gene (2020) primary study Strong

    VNS upregulates miR-183-3p which directly targets BNIP3L, reducing autophagy and improving chronic systolic heart failure in rats.

    DOI: 10.1016/j.gene.2019.144136
  17. Hemoglobin and Hematocrit Inversely Correlate With Systolic Function in Heart Failure Journal of Cardiac Failure (2010) Thin

    This study investigates the association between mean corpuscular hemoglobin concentration (MCHC) and cardiac function in patients with chronic systolic heart failure, finding that lower MCHC levels correlate with worse clinical outcomes independent of anemia.

    DOI: 10.1016/j.cardfail.2010.06.065
  18. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure European Heart Journal (2008) Thin

    Elevated plasma methylated arginine metabolites, especially ADMA, associate with LV diastolic dysfunction and adverse prognosis in chronic systolic heart failure, with ADMA independently predicting long-term outcomes and beta-blocker use linked to lower ADMA and MMA levels.

    DOI: 10.1093/eurheartj/ehn360
  19. Assessment of Longitudinal and Radial Ventricular Dyssynchrony in Ischemic and Nonischemic Chronic Systolic Heart Failure: A Two-Dimensional Echocardiographic Speckle-Tracking Strain Study Journal of the American Society of Echocardiography (2008) primary study Strong

    In chronic systolic heart failure, electrical and mechanical ventricular dyssynchrony correlate better in nonischemic than ischemic cardiomyopathy, and radial 2D speckle-tracking strain correlates with QRS width in both subgroups.

    DOI: 10.1016/j.echo.2007.05.031
  20. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population Cardiology (2015) Thin

    This study investigates the effects of combining ivabradine with various β-blockers, particularly carvedilol, on cardiovascular outcomes in patients with chronic systolic heart failure, demonstrating significant improvements in outcomes with the combination therapy.

    DOI: 10.1159/000380812
  21. Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure Journal of the American Heart Association (2014) Thin

    This study evaluates the prognostic value of longitudinal, circumferential, and radial strain and strain rate in patients with chronic systolic heart failure, demonstrating that strain provides incremental predictive value beyond ejection fraction for adverse outcomes.

    DOI: 10.1161/JAHA.113.000550
  22. Iron deficiency: an ominous sign in patients with systolic chronic heart failure European Heart Journal (2010) Thin

    This study investigates the prevalence of iron deficiency in patients with systolic chronic heart failure and its association with increased mortality risk, highlighting the need for iron supplementation as a potential therapeutic approach.

    DOI: 10.1093/eurheartj/ehq158
  23. Morphologic and Topologic Characteristics of Coronary Venous System Delineated by Noninvasive Multidetector Computed Tomography in Chronic Systolic Heart Failure Patients Journal of Cardiac Failure (2007) Thin

    This study investigates the morphologic and topologic characteristics of the coronary venous system in patients with chronic systolic heart failure using noninvasive multidetector computed tomography, revealing significant differences in venous length and angulation compared to …

    DOI: 10.1016/j.cardfail.2007.02.007
  24. Effects of ivabradine on endothelial function, aortic properties and ventricular‐arterial coupling in chronic systolic heart failure patients Cardiovascular Therapeutics (2018) Thin

    This study evaluates the short-term effects of ivabradine on endothelial function, aortic properties, and ventricular-arterial coupling in patients with chronic systolic heart failure, finding significant improvements in these parameters after four months of treatment.

    DOI: 10.1111/1755-5922.12323
  25. Prognostic stratification of patients with chronic systolic heart failure using biomarkers and Doppler echocardiography Journal of Cardiovascular Medicine (2014) Thin

    In chronic systolic heart failure patients, a restrictive left-ventricular filling pattern (RFP) on Doppler echocardiography is the strongest prognostic indicator, and adding plasma BNP or high-sensitivity troponin I does not meaningfully improve prognostic stratification.

    DOI: 10.2459/JCM.0000000000000034
  26. B-Cell Reconstitution in a SCID Mouse Restores CMP Phenotype Journal of Cardiac Failure (2013) Thin

    This study investigates the prognostic value of improvement in left ventricular global longitudinal strain (GLS) in chronic systolic heart failure patients undergoing beta-blocker therapy, finding that such improvement correlates with better myocardial structure and clinical out…

    DOI: 10.1016/j.cardfail.2013.06.171

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →